Discovery of a potent, selective, and orally bioavailable c-met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Arican O, Ozturk P, Kurutas EB, Unsal V
Increased DNA damage leads to increased parylation, causing mitochondrial dysfunction
In many cases, the disease may be confused with other parkinsonian disorders, where a careful recording of history, e.g., exposure to pesticides, encephalitis, certain antipsychotic drugs, or the presence of certain exclusion criteria or brain imaging studies may help to clinch the diagnosis
Your Journey Our medical team will guide you through every step once SLU-PP-332 becomes available
and physical therapy (vacuum devices and/or penile traction devices, iontophoresis, extracorporeal shock wave therapy (ESWT), and so on) [9, 10]